Please ensure Javascript is enabled for purposes of website accessibility

With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market

By Jason Hawthorne - May 7, 2021 at 6:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One company is setting itself apart in a crowded field.

Long before they won the 2020 Nobel Prize in Chemistry for discovering the molecular gene-editing tool known as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, Jennifer Doudna and Emmanuelle Charpentier dreamed of Victoria Gray, a woman with sickle cell disease. Although they didn't know her, they knew that one day, a patient with a genetic disease would be cured using their discovery. 

Sickle cell disease was the logical place to start since it's the most common blood disorder with a single-gene mutation. CRISPR Therapeutics (CRSP -4.92%) is one of several companies using gene editing to fight the illness. Their drug CTX001, developed with partner Vertex Pharmaceuticals, is changing the outlook for patients.

Nearly two years after receiving her first treatment, Gray is free of the excruciating episodes and hospital stays that had become the norm in her 35 years. She isn't the only one, and the company is planning to leverage that success to take on a far more prevalent disease.

A gloved hand holding a small container labeled CRISPR as someone puts a drop of liquid inside.

Image source: Getty Images.

Proof of concept

In sickle cell disease, the red blood cells become C-shaped, as well as get hard and sticky. This causes them to clog the blood flow, leading to everything from excruciating pain to infection and stroke.

To combat this, the company uses CRISPR-Cas9 to edit a gene called BCL11A. A few months after birth, that gene triggers the body to stop making a type of blood called fetal hemoglobin and begin making adult hemoglobin. It turns out the fetal hemoglobin is much more effective at carrying oxygen. By turning the gene off, the body goes back to producing high amounts of it. That elevated level prevents the patients red blood cells from sickling.

At the American Society for Hematology (ASH) conference in December, results from the first 10 patients were shared. They ranged between three and 18 months removed from the treatment. All were progressing well. The company plans to treat a total of 45 patients in the study. 

The next target

CRISPR's next set of programs are cell-therapy products for immuno-oncology. These are cancer treatments that harness the body's immune system. The company is creating its own gene-edited allogeneic, or "off-the-shelf," chimeric antigen receptor (CAR-T) cells.

These cells are engineered to target a specific protein. Traditional CAR-T cells are taken from a patient and modified. Although these have proven useful in a select subset of cancers, issues such as extreme toxicity, complex manufacturing, and low potency have limited their applicability.

CRISPR's approach would improve standardization and availability of the treatment, as well as increasing the range of cancers able to be targeted. That range could include solid tumors, a category that makes up 90% of cancers in adults.

CRISPR's immuno-oncology research is focused on three targets. The first is CD19, a molecule that's targeted in about 50% of all CAR-T programs. The second target is B-cell maturation agent (BCMA) for the treatment of multiple myeloma. The final target is CD70, a more novel approach that should enable applications in both solid tumors and blood cancers. These are in clinical development under the labels CTX110, CTX120, and CTX130, respectively.

The future of medicine

Despite its success, CRISPR is still in its early stages and will face plenty of competition. Both Editas Medicine and Intellia Therapeutics are employing CRISPR-Cas9, while Beam Therapeutics is attempting to commercialize a related base editing approach. Meanwhile, more than 100 companies across the globe continue developing CAR-T technologies.

One tailwind is familiarity. The success of COVID-19 vaccines based on messenger RNA has raised the profile of genetic medicine. That already appears to be flowing into research. In their most recent quarterly earnings calls, both Thermo Fisher Scientific and Repligen -- life sciences companies -- called out genetic sciences and gene therapy as areas of particular strength. 

CRISPR Therapeutics has a head start in using gene editing to cure disease. That said, Intellia and Beam's approaches could prove easier or more effective. That's why it's a good idea to keep investments in biotechs small and spread across several companies. It's virtually impossible to predict the future, and that's even truer regarding scientific advances.

However, with an apparent cure for sickle cell disease behind it and programs to genetically enhance our immune system to kill cancer, CRISPR Therapeutics is leading the race to become the future of medicine. The stock is nearly 50% off its highs, the biggest discount since the depths of the pandemic. Now may be the perfect time to pick up shares for investors who can stomach the volatility and hold for the long term.

Jason Hawthorne owns shares of CRISPR Therapeutics. The Motley Fool owns shares of and recommends CRISPR Therapeutics, Editas Medicine, and Repligen. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$68.60 (-4.92%) $-3.55
Beam Suntory Inc. Stock Quote
Beam Suntory Inc.
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$299.04 (1.61%) $4.75
Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
$588.55 (-1.09%) $-6.46
Repligen Corporation Stock Quote
Repligen Corporation
$237.75 (-1.43%) $-3.46
Intellia Therapeutics Stock Quote
Intellia Therapeutics
$56.30 (-5.33%) $-3.17
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$14.72 (-7.65%) $-1.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.